| Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium IG McKeith, DW Dickson, J Lowe, M Emre, JT O'brien, H Feldman, ... Neurology 65 (12), 1863-1872, 2005 | 5739 | 2005 |
| Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium IG McKeith, BF Boeve, DW Dickson, G Halliday, JP Taylor, D Weintraub, ... Neurology 89 (1), 88-100, 2017 | 3347 | 2017 |
| The AD8: a brief informant interview to detect dementia JE Galvin, CM Roe, KK Powlishta, MA Coats, SJ Muich, E Grant, JP Miller, ... Neurology 65 (4), 559-564, 2005 | 1069 | 2005 |
| Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis Y Iturria-Medina, RC Sotero, PJ Toussaint, JM Mateos-Pérez, AC Evans Nature communications 7 (1), 11934, 2016 | 990 | 2016 |
| Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial JF Quinn, R Raman, RG Thomas, K Yurko-Mauro, EB Nelson, C Van Dyck, ... Jama 304 (17), 1903-1911, 2010 | 887 | 2010 |
| Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein P Tu, JE Galvin, M Baba, B Giasson, T Tomita, S Leight, S Nakajo, ... Annals of neurology 44 (3), 415-422, 1998 | 740 | 1998 |
| Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease HI Hurtig, JQ Trojanowski, J Galvin, D Ewbank, ML Schmidt, VMY Lee, ... Neurology 54 (10), 1916-1921, 2000 | 722 | 2000 |
| DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers CF Lippa, JE Duda, M Grossman, HI Hurtig, D Aarsland, BF Boeve, ... Neurology 68 (11), 812-819, 2007 | 680 | 2007 |
| Synucleinopathies: clinical and pathological implications JE Galvin, VMY Lee, JQ Trojanowski Archives of neurology 58 (2), 186-190, 2001 | 571 | 2001 |
| Axon pathology in Parkinson’s disease and Lewy body dementia hippocampus contains α-, β-, and γ-synuclein JE Galvin, K Uryu, VMY Lee, JQ Trojanowski Proceedings of the National Academy of Sciences 96 (23), 13450-13455, 1999 | 517 | 1999 |
| Validity and reliability of the AD8 informant interview in dementia JE Galvin, CM Roe, C Xiong, JC Morris Neurology 67 (11), 1942-1948, 2006 | 468 | 2006 |
| Research criteria for the diagnosis of prodromal dementia with Lewy bodies IG McKeith, TJ Ferman, AJ Thomas, F Blanc, BF Boeve, H Fujishiro, ... Neurology 94 (17), 743-755, 2020 | 437 | 2020 |
| Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease AS Fleisher, R Raman, ER Siemers, L Becerra, CM Clark, RA Dean, ... Archives of neurology 65 (8), 1031-1038, 2008 | 433 | 2008 |
| Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease ER Siemers, JF Quinn, J Kaye, MR Farlow, A Porsteinsson, P Tariot, ... Neurology 66 (4), 602-604, 2006 | 421 | 2006 |
| Distinguishing Alzheimer’s disease from other major forms of dementia S Karantzoulis, JE Galvin Expert review of neurotherapeutics 11 (11), 1579-1591, 2011 | 397 | 2011 |
| A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease M Sano, KL Bell, D Galasko, JE Galvin, RG Thomas, CH Van Dyck, ... Neurology 77 (6), 556-563, 2011 | 364 | 2011 |
| Longitudinal study of the transition from healthy aging to Alzheimer disease DK Johnson, M Storandt, JC Morris, JE Galvin Archives of neurology 66 (10), 1254-1259, 2009 | 361 | 2009 |
| Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease MM Williams, C Xiong, JC Morris, JE Galvin Neurology 67 (11), 1935-1941, 2006 | 294 | 2006 |
| Clinical phenotype of Parkinson disease dementia JE Galvin, J Pollack, JC Morris Neurology 67 (9), 1605-1611, 2006 | 292 | 2006 |
| Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE S Ayton, NG Faux, AI Bush Nature communications 6 (1), 6760, 2015 | 289 | 2015 |
